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Gene targeting strategies have become a powerful technology for elucidating mammalian
gene function. The recently generated knockout (KO)-first strategy produces a KO at
the RNA processing level and also allows for the generation of conditional KO alleles
by combining FLP/FRT and Cre/loxP systems, thereby providing high flexibility in gene
manipulation. However, this multipurpose KO-first cassette might produce hypomorphic
rather than complete KOs if the RNA processing module is bypassed. Moreover, the
generation of a conditional phenotype is also dependent on specific activity of Cre
recombinase. Here, we report the use of an efficient molecular biological approach to test
pannexin1 (Panx1) mRNA expression in global and conditional Panx1 KOmice derived from
the KO-first mouse line, Panx1tm1a(KOMP)Wtsi. Using qRT-PCR, we demonstrate that tissues
from wild-type (WT) mice show a range of Panx1 mRNA expression levels, with highest
expression in trigeminal ganglia, bladder and spleen. Unexpectedly, we found that in mice
homozygous for the KO-first allele, Panx1 mRNA expression is not abolished but reduced
by 70% compared to that of WT tissues. Thus, Panx1 KO-first mice present a hypomorphic
phenotype. Crosses of Panx1 KO-first with FLP deleter mice generated Panx1f/f mice.
Further crosses of the latter mice with mGFAP-Cre or NFH-Cre micewere used to generate
astrocyte- and neuron-specific Panx1 deletions, respectively. A high incidence of ectopic
Cre expression was found in offspring of both types of conditional Panx1 KO mice. Our
study demonstrates that Panx1 expression levels in the global and conditional Panx1
KO mice derived from KO-first mouse lines must be carefully characterized to ensure
modulation of Panx1 gene expression. The precise quantitation of Panx1 expression and
its relation to function is expected to provide a foundation for future efforts aimed at
deciphering the role of Panx1 under physiological and pathological conditions.
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INTRODUCTION
Pannexins are a group of proteins that share some sequence
homology with the invertebrate gap junctions, the innexins, and
because of that are considered to be members of this family.
Three Pannexins (Panx1, Panx2, and Panx3) are present in mam-
malian tissues (Panchin et al., 2000). They have no sequence
homologies with the chordate gap junction proteins, connexins,
but membrane topology predicts similar four transmembrane
domains with cytosolic N- and C- termini. Panx1 is ubiqui-
tously expressed while Panx2 is restricted to the CNS and Panx3
is mainly found in cartilage and dermis (Baranova et al., 2004;
Barbe et al., 2006; Penuela et al., 2007). Of the three, Panx1 is
best characterized, forming high conductance plasma membrane
channels with a maximal conductance of 500 pS that are perme-
able to ATP and modulated by intracellular signaling molecules
(calcium, tyrosine kinase, caspases) (Bao et al., 2004; Locovei
et al., 2006a; Pelegrin and Surprenant, 2006; Iglesias et al., 2008;
Abbreviations: Panx1, pannexin1; CNS, central nervous system; PNS, periph-
eral nervous system; RT-PCR, reverse transcription-polymerase chain reaction;
qRT-PCR, quantitative real time RT-PCR; GFAP, glia fibrillary acidic protein; NFH,
neurofilament H; WT, wild-type; KO, knockout.
Sandilos and Bayliss, 2012). Panx1 channel activity can be mod-
ulated by mechanical stretch, membrane potential, cytoplasmic
Ca2+ concentration (Bao et al., 2004; Locovei et al., 2006b),
and by ATP directly or via purinergic receptors (Locovei et al.,
2006b, 2007; Pelegrin and Surprenant, 2006; Qiu andDahl, 2009).
Panx1 channels are permeable to ATP (Bao et al., 2004; Locovei
et al., 2006a) and thus contribute to purinergic signaling includ-
ing that involved in the propagation of intercellular calciumwaves
between astrocytes (Scemes et al., 2007; Suadicani et al., 2012),
communication between taste bud cells (Huang et al., 2007), neu-
trophil activation and immune defense (Chen et al., 2010), and
vascular tone (Billaud et al., 2012). Several studies indicate the
involvement of Panx1 in certain pathophysiological conditions
(ischemia, seizures, innate immune response, ATP-induced cell
death, HIV infection, etc.) [reviewed in Scemes et al., 2009; Dahl
and Keane, 2012].
Over the last few years at least four different transgenic mouse
lines have been generated to knockdown Panx1 expression: the
Monyer (single and double Panx1 and Panx2 KO (Bargiotas et al.,
2011), the Knockout Mouse Project (KOMP; www.KOMP.org),
the Genentech (www.genentech.com), and the Miami (Romanov
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et al., 2012) mice. While the former mice were generated by intro-
ducing a lacZ and a neomycin cassette within exon 1 of Panx1
(Bargiotas et al., 2011), hence disrupting the gene transcription,
the other three Panx1-null mice were designed using approaches
that allow for both global deletion as well as cell-specific dele-
tion. The Genentech and the Miami mouse lines were generated
using the “conditional first” strategy, which relies on the creation
of a conditional allele which when crossed with a Cre-deleter or
a promoter specific-Cre mouse removes the loxP flanked region
for transmission of the knockout (KO) or conditional allele. The
KOMPmouse is based on the KO-first strategy (Testa et al., 2004)
involving the insertion of a cassette into the first intron of Panx1
that produces a KO at the transcript level, due to the presence of
a splice acceptor in the cassette that captures the transcript. Thus,
mice homozygous for the KO-first cassette are Panx1-null; how-
ever, a hypomorphic phenotype may result if the KO function of
the RNA processing module is bypassed. For cell-specific KO, the
KO-first allele was designed with two FRT sites flanking the cas-
sette containing the splice acceptor and loxP sites flanking Panx1
exon 2. Conditional KO mice can be generated by crossing Panx1
KO-first mice with flippase deleter mice, hereby inducing excision
of the cassette at the FRT sites. This restores gene function and
leaves Panx1 exon 2 flanked by 2 loxP sites. The use of appropri-
ate Cre expressing mouse lines then allows for a cell-type specific
Panx1 gene deletion.
Here we provide a molecular biological approach that allows
for the evaluation of the state of knockdown of Panx1 in the global
and conditional Panx1 KO mice from KOMP. Our results indi-
cate that global Panx1 KO mice (homozygous KO-first alleles)
have a hypomorphic phenotype, with about 70% reduction of
Panx1 mRNA in 10 tissues that were analyzed. In the conditional
Panx1 KO, our study indicates significant ectopic expression of
Cre recombinase when using either mGFAP or the mNFH pro-
moters to generate glia- and neuron-specific deletion of Panx1,
respectively. We also describe a useful tail qRT-PCR method to
readily detect such ectopic activity.
MATERIALS AND METHODS
ANIMALS
The Panx1-null mouse line (Panx1tm1a(KOMP)Wtsi), generated by
KOMP (www.KOMP.org) in the C57BL/6 background, uses a
construct that introduces a floxed locus so that cell-type specific
KO can be achieved through breeding with a Cre recombi-
nase mouse. KOMP mice are maintained in our animal facility
at Albert Einstein College of Medicine as global Panx1 knock-
out (Panx1 KO-first) and wild-type (WT) Panx1 (Panx1+/+).
Panx1f/f mice were generated by crossing Panx1 KO-first with
flippase deleter mice (B6.ACTFLPe/J) to allow targeted knock-
down of Panx1 in either astrocytes or neurons after crossing
with cell-type specific Cre mice. For that, mGFAP-Cre (B6.Cg-
Tg(Gfap-cre)73.12Mvs/J) andmNFH-Cre (Tg(Nefh-cre)12Kul/J)
mice in the C57BL/6 background were purchased from Jackson
laboratory and were used to generate mGFAP-Cre:Panx1f/f and
mNFH-Cre:Panx1f/f mice that aremaintained in our animal facil-
ity. For some studies, we also used the Panx1−/− mouse line
(Bargiotas et al., 2011), which was maintained at the animal
facility of the University of Geneva. All studies were performed
following protocols approved by the Albert Einstein Animal Care
and Use Committee.
GENOTYPING
As previously described (Santiago et al., 2011), Panx1 KO-
first mice were genotyped by tail PCR using two forward
(F1a, F1b) and two reverse (R1a, R1b) primers (F1a: GAGAT
GGCGCAACGCAATTAAT; R1a: CTGGCTCTCATAATTCTT
GCCCTG; F1b: CTGTATCACACAACCACTTCAGAGAAGG;
R1b: GAGCTGACCCCTTTCCATTCAATAG3). The WT Panx1
allele was targeted by primers F1a and R1a and identified as a
579 bp amplicon, while the transgene was targeted by primers
F1b and R1b and identified as a 381 bp amplicon (Figure 1).
TISSUE PREPARATION
Six month old WT and Panx1 KO-first mice were anesthetized
with isoflurane and exsanguinated by intracardiac perfusion with
ice-cold phosphate buffered saline, pH 7.4. The tissues were
immediately removed, transferred to vials with RNAlater solu-
tion (Ambion, Life Technologies, Grand Island, NY), and stored
at 4◦Cuntil processing for qRT-PCR analysis. Tissue samples were
collected from tail tips, nervous system (cortex, hippocampus,
cerebellum, trigeminal ganglia), heart (apex region), bone (cal-
varia), spleen, urinary bladder, liver (middle lobe), and kidney
(cortical and medullar regions).
RT-PCR
Primers used for Panx1 mRNA coding region were F: ATGGCCA
TCGCCCACTTG R: GCAGGACGGATTCAGAAGCC (1278 bp).
Reaction mixtures using Multiplex PCR kit (Qiagen) with tar-
geted cDNA were denatured at 95◦C for 10min, followed by
40 PCR cycles. Each cycle consisted of the following three steps:
94◦C for 30 s, 55◦C for 30 s, and 72◦C for 90 s. Final extension
was set at 72◦C for 10min.
qRT-PCR
Tissues of adult mice (Panx1 WT, Panx1 KO-first, Panxf/f,
GFAP-Cre:Panx1f/f, and NFH-Cre:Panxf/f) were used to quan-
tify the levels of Panx1 transcripts. Tissues were minced and
homogenized with a Bullet Blender (Next Advance Inc.) and
total RNA was extracted using the RNeasy fibrous tissue or
plus mini kits (Qiagen) according to the manufacturer’s proto-
col. Complementary DNA was synthesized from 1μg/10μl of
RNA, using a Superscript VILO cDNA Synthesis Kit (Invitrogen).
Primers used are Pannexin1 (F: AGCCAGAGAGTGGAGTTCA
AAGA; R: CATTAGCAGGACGGATTCAGAA) and 18S riboso-
mal RNA (F: CACGGCCGGTACAGTGAAAC; R: AGAGGAGC
GAGCGACCAAA). GAPDH primers (F: CAAGGCTGTGGGCA
AGGTCA; R: CATCATACTTGGCAGGTTTC). GAPDH and 18S
were used as house-keeping genes for normalization. Real-time
RT–PCRwas performed using SYBR Green PCRMaster Mix with
7300 Fast Real-Time PCR system (Applied Biosystems). Reaction
mixtures were denatured at 95◦C for 10min, followed by 40 PCR
cycles. Each cycle consisted of the following three steps: 94◦C for
15 s, 57◦C for 15 s, and 72◦C for 1min. Each sample was normal-
ized against internal controls (18S ribosomal or GAPDH RNAs);
the relative values for target abundance was extrapolated from
standard curves generated from the reference standard.
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FIGURE 1 | Schematic view of the Panx1wild-type allele and the
“knockout-first” conditional allele of Panx1 tm1a(KOMP)Wtsi mice. Pannexin1
(Panx1) gene consists of 5 exons. Panx1 “knockout-first” allele was generated
by KOMP through insertion of the L1L2_Bact_P cassette into themouse Panx1
gene at position 15010456 of Chromosome 9. The cassette is composed of
2FRT sites flanking an IRES:lacZ trapping cassette and a floxed human beta
actin promoter-driven neo cassette inserted into the intron 1 of Panx1 and an
additional third loxP site downstream, at position 15009768, of Panx1 exon 2,
the critical exon. This “knockout-first” allele is designed to generate a Panx1
null allele through splicing exon 1 to a lacZ trapping element and disrupting
Panx1mRNA expression. The trapping cassette also includes the mouse En2
splice acceptor (En2 SA) and the SV40 polyadenylation sequences. Position of
primers used for genotyping (two primer sets: F1a—R1a and F1b—R1b), for
RT-PCR (primer set F2—R2), and for qRT-PCR (primer set F3—R3) with
expected amplicon length are indicated. attL1 and attL2: sites for site-specific
recombination of the entry clone. FRT: sites for flippase activity. EN2-SA: splice
acceptor ofmouseengrail (En2) exon2. IRES, internal ribosomeentry site; lacZ,
gene encoding β-galactosidase; pA, polyadenylation signal; neo, neomycin
phosphotransferase; loxP sites (triangles); target sites for Cre recombinase.
Adapted from www.KOMP.org.
IMMUNOHISTOCHEMISTRY
Trigeminal ganglia from WT, Panx1 KO-first, Panx1f/f and con-
ditional Panx1 KO (GFAP-Cre:Panx1f/f and NFH-Cre:Panx1f/f)
mice were removed from animals anesthetized with isoflurane
and sacrificed by decapitation. Isolated trigeminal ganglia were
then fixed in 4% p-formaldehyde overnight and incubated in 30%
sucrose for 48 h. Tissues were then embedded in O.C.T, cryosec-
tioned (12μm), incubated with blocking solution containing
0.4% Triton-X, and immunostained with a Panx1 antibody and
with neuronal (NeuN) or glial (glutamine synthase) markers.
The primary antibodies used were: chicken anti-Panx1 (1:500;
extracellular loop epitope: VQQKSSLQSES; Aves Lab #6358);
mouse anti-NeuN (1:100; Millipore); goat anti-glutamine syn-
thase (1:200; Santa Cruz). Secondary Alexa conjugated antibodies
(1:2000) were: goat anti-chicken, goat anti-mouse, and donkey
anti-goat. Images were acquired using an Olympus FluoView
300 confocal laser scanning microscope equipped with a 40×
water-immersion lens (0.80 NA), and FITC, TRITC, and UV filter
sets.
RESULTS
PRESENCE OF PANNEXIN1 mRNA IN PANNEXIN1 KO-FIRST MICE
The Panx1 transgenic mice generated by KOMP using the KO-
first strategy (Testa et al., 2004) result from the insertion into
intron 1 of the Panx1 gene of a cassette containing a splice
acceptor that captures the nascent RNA and a polyadenylation
signal that truncates the transcript downstream of the cassette
(Figure 1). Depending on the intron, this type of construct can
yield either a KO or a hypomorphic allele, in case of alternative
splicing or the presence of a downstream promoter.
Heterozygous Panx1 KO-first purchased from KOMP were
bred to obtain homozygous WT and Panx1 KO-first mice
(Figure 2A). To evaluate whether Panx1 KO-first mice repre-
sent a complete KO or a hypomorphic phenotype with residual
Panx1 transcript, we designed RT-PCR primers (set F2—R2 in
Figure 1) to detect Panx1 mRNA coding region in tissues of WT
and Panx1 KO-first adult mice. As shown in Figure 2B, Panx1
KO-first mice displayed amplicons corresponding to the entire
Panx1 mRNA region (1278 bp) similar to WT (C57Bl/6N and
C57Bl/6J) mice, confirming that the KO-first strategy did not
completely prevent Panx1 transcription. In addition, extraction
of bands from the RT-PCR gel for further amplification, using
primer sets spanning exons 4 and 5 of Panx1, confirmed that
the KO-first trapping cassette could be bypassed (Figure 2B, bot-
tom), allowing for transcription of the entire Panx1mRNA in the
Panx1 KO-first mice. Note, in Figure 2B Panx1 mRNA expres-
sion is shown qualitatively, but not quantitatively. To quantify
the extent of Panx1 deletion (i.e., efficiency of the KO-first trap-
ping cassette), we performed qRT-PCRusing primers (set F3—R3
in Figure 1; downstream of the trapping cassette) and tail tip
samples from 3 WT and 3 KO-first adult mice.
After normalization of ct values of Panx1 to those obtained for
control 18S, Panx1mRNA expression levels recorded from Panx1
KO-first were compared to those obtained from WT samples. As
indicated in Figure 2C, we measured about 50% reduction of
Panx1 mRNA in tail tips of Panx1 KO-first relative to that of WT.
Thus, our results indicate that transcription of Panx1 mRNA
is only partially ablated in the Panx1 KO-first mouse.
HYPOMORPHIC PHENOTYPE OF PANNEXIN1 KO-FIRST MICE
Pannexin1 is ubiquitously expressed, but its expression levels in
different tissues have not previously been quantified.We therefore
measured Panx1mRNA levels in various tissues of threeWTmice
by qRT-PCR using primers (set F3—R3 in Figure 1) spanning
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FIGURE 2 | Panx1 KO-first mice express Panx1 mRNA. (A) Tail PCR
products obtained using specific primers (primer sets F1a—R1a and
F1b—R1b depicted in Figure 1) designed to detect wild-type (579bp
amplicon; lane 7), homozygous Panx1 KO-first (381bp amplicon; lanes 3 and
6) and the heterozygous (579 and 381bp amplicons; lanes 1, 2, 4, and 5)
alleles. Data are from a litter derived from heterozygous breeding. (B) Top:
RT-PCR products obtained from tissues of wild-type (WT) and Panx1 KO-first
(KO) using primers (primer set F2—R2 depicted in Figure 1) designed to
detect wild-type Panx1 mRNA (1278bp) coding region. T. ganglia, trigeminal
ganglia; sp, spleen; br, brain; nt, no template. Bottom: PCR products obtained
from RT-PCR amplicons extracted from gel on top part using primers
spanning exons 4 and 5 of Panx1 (primer set F3—R3 depicted in Figure 1).
Wild-type (lane 1) and Panx1 KO-first (lane 2) trigeminal ganglia, Panx1 cDNA
plasmid (lane 3), and no template (lane 4). (C) Histograms of the mean ±
s.e.m. values of Panx1 mRNA expression levels detected from tail tips of
wild-type (WT) and Panx1 KO-first (KO) mice by qRT-PCR using primer set
F3—R3. Statistical significance obtained by unpaired T -test, N = 3 mice per
group.
exons 4 and 5. Comparison of Panx1 mRNA expression levels
(normalized to 18 S) identified highest Panx1 levels in trigeminal
ganglia of the PNS (t. ganglia; 17.12e-005), followed by bladder
(14.05e-005) and spleen (10.94e00-5) (Figure 3A). Panx1 mRNA
expression levels were 4–10 times lower in the CNS compared to
t. ganglia and differed in various brain regions (cortex: 4.772e-
005, hippocampus: 6.28 e-005, cerebellum: 1.705e-005). Similar
results were obtained when Panx1 mRNA were normalized to
GAPDH (data not shown).
We next evaluated by qPCRwhether down-regulation of Panx1
transcript occurred in a homogeneous fashion across different
tissues from Panx1 KO-first mice. Tissues of at least 3 mice per
genotype were used; no siblings were used and not all tissues
were from the same set of animals. We found that Panx1 mRNA
expression was similarly reduced by 70% in all Panx1 KO-first
tissues analyzed compared to their respective tissue in WT mice.
Figure 3B shows Panx1mRNA levels in Panx1 KO-first mice nor-
malized to those of WT mice, which are (mean ± s.e.m.): cortex
(WT: 1.0 ± 0.11; KO: 0.34 ± 0.06), hippocampus (WT: 1.0 ±
0.22; KO: 0.31 ± 0.008), cerebellum (WT: 1.0 ± 0.02; KO: 0.25),
trigeminal ganglia (WT: 1.0 ± 0.02; KO: 0.34 ± 0.008), calvaria
(WT: 1.0 ± 0.09; KO 0.33 ± 0.034), heart (WT: 1.0 ± 0.15; KO
0.3 ± 0.18), bladder (WT: 1.0 ± 0.22; KO: 0.46 ± 0.05), spleen
(WT: 1.0 ± 0.12; KO: 0.34 ± 0.22), kidney (WT: 1.0 ± 0.07; KO:
0.35 ± 0.03), and liver (WT: 1.0 ± 0.08; KO: 0.28 ± 0.03).
These results indicate that the KO-first cassette leads to a simi-
lar reduction of Panx1mRNA in all tissues tested, and that, for any
given tissue, the variability between animals was low, as evaluated
by the s.e.m. values.
Using this same set of primers and qPCR conditions, we
evaluated Panx1 levels in another transgenic mouse line, the
Panx1−/− (Bargiotas et al., 2011). Compared to Panx1 KO-first,
Panx1 mRNA levels measured from hippocampi of Panx1−/−
mice was markedly reduced (Panx1+/+: 0.99 ± 0.12; Panx1−/−:
0.01 ± 0.003; Figure 3C), further confirming the hypomorphic
phenotype of the Panx1 KO-first.
Immunohistochemistry performed on trigeminal ganglia
isolated from WT and Panx1 KO-first indicated that the
remaining 30% Panx1 mRNA in the KO-first tissue did not result
in detectable Panx1 protein (Figures 3D,E).
CONDITIONAL, CELL-SPECIFIC Panx1 KO MICE: GFAP-Cre:Panx1f/f AND
NFH-Cre:Panx1f/f
One of the advantages of the KO-first strategy is the possibil-
ity of generating conditional deletion of the gene of interest. By
crossing Panx1 KO-first with flippase deleter mice, the KO-first
cassette flanked by FRT sites is removed, and Panx1 gene function
is restored, leaving 2 loxP sites flanking exon 2 of Panx1. Crossing
these floxed Panx1 mice with mice expressing Cre recombi-
nase under cell-specific promoters allows for the generation of
conditional KO mice (Figure 4).
To evaluate the extent to which Panx1 mRNA expression was
restored after removal of the KO-first cassette, we performed qRT-
PCR on tail tip samples of Panx1f/f and compared that to WT
samples. As shown in Figure 5, we found that in 26 Panx1f/f mice
Panx1mRNA was 1.22 ± 0.08 fold that of WT mice.
We then generated conditional astrocyte- and neuron-specific
Panx1 KO mice by crossing Panx1f/f with either mGFAP-Cre
or mNFH-Cre mice, respectively. Cre-recombinase displays high
incidence of ectopic activity, leading to non-cell-type specific
target deletion (Schmidt-Supprian and Rajewsky, 2007). We
therefore developed a strategy to detect ectopic Cre activity
in the tail of GFAP-Cre:Panx1f/f and NFH-Cre:Panx1f/f mice
using qRT-PCR to determine Panx1 mRNA expression levels.
We considered that if mice showed tail levels of Panx1 mRNA
expression level less than 80% that of Panx1+/+ mice, they
were likely to exhibit ectopic Cre expression, since reduced
Panx1 mRNA expression in the tail would most likely be
due to off target deletion of Panx1. Based on this considera-
tion, we found that 16.7% (4/24) NFH-Cre:Panx1f/f and 52.6%
(10/19) GFAP-Cre:Panx1f/f offspring from Panx1f/f females and
Cre:Panx1f/f males had less than 80% Panx1 mRNA compared
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FIGURE 3 | Panx1 mRNA expression is decreased by 70% in tissues
from Panx1 KO-first mice. (A) Panx1 mRNA expression levels (normalized
to 18S RNA) obtained by qRT-PCR from various tissues of wild-type mice
using primers spanning exons 4 and 5 of Panx1 (primer set F3—R3
depicted in Figure 1). (B) Bar histograms of the mean ± s.e.m. values
of Panx1 mRNA obtained by qRT-PCR of various tissues of wild-type
(black bars) and Panx1 KO-first (white bars) mice. Panx1 KO-first mRNA
expression levels (normalized to that of 18S) was calculated relative to
those of wild-type. RNA was extracted from 10 different tissues of 3 mice
per genotype. Dotted line represents the mean ± s.e.m. value of Panx1
mRNA level (relative to WT) obtained from all tissues of Panx1 KO-first
mice. (C) Bar histograms of the mean ± s.e.m. values of Panx1 mRNA
obtained by qRT-PCR of hippocampi of KOMP (WT and Panx1 KO-first) and
Monyer (Panx1+/+ and Panx1−/−) mice. RNA was extracted from tissues
of 3 mice per genotype and mRNA expression levels (normalized to 18S)
was calculated relative to those of their respective wild-types.
(D,E) Confocal images of (D) WT and (E) Panx1 KO-first trigeminal ganglia
immunostained with anti-Panx1 antibody (red) and counterstained with
DAPI (blue). N indicates neurons and white arrowheads indicate satellite
glia cells surrounding neuronal cell bodies. Bar: 50μm.
to WT controls (Figure 5). We found that about 34% Panx1f/f
littermates (offspring of Panx1f/f and mNFH-Cre:Panx1f/f or
mGFAP-Cre:Panx1f/f) had lower Panx1 mRNA expression in tail
tip samples (0.69 ± 0.03 fold; N = 11 mice) compared to WT
mice. No significant differences in 18S RNA levels were detected
among these samples. This reduced expression of Panx1 mRNA
in Panx1f/f (littermates of conditional Panx1 KO mice) com-
pared to those detected from offspring of Panx1f/f and Panx1f/f
mice, most likely relates to the transient expression of Cre in
the germlines of Panx1f/f derived from GFAP-Cre or mNFH-Cre
crosses.
Mice that did not show ectopic Cre activity were then evalu-
ated for Panx1 deletion in glia and neuronal cells using trigem-
inal ganglia processed for immunohistochemistry. As shown in
Figure 6, Panx1 expression in satellite glial cells (Figures 6B,E)
and in neurons (Figures 6C,F) was significantly reduced in
the trigeminal ganglia of GFAP-Cre and NFH-Cre:Panx1f/f
mice, respectively, compared to that found in Panx1f/f ganglia
(Figures 6A,D).
DISCUSSION
Here we characterized Panx1 expression in WT and transgenic
Panx1 mice developed by KOMP. Although Panx1 is ubiqui-
tously expressed in WT mice, we detected different levels of
Panx1 mRNA in distinct tissues, with highest Panx1 levels in
trigeminal ganglia, bladder and spleen. Transgenic Panx1 mice
from KOMP were generated using a KO-first approach, which
allows generation of global KO or conditional KO mice. We
found that Panx1 KO-first mice represent a hypomorphic phe-
notype, and not a complete KO. Moreover, Panx1 mRNA was
similarly reduced by 70% in all tissues derived from Panx1 KO-
first mice compared to the level of each respective WT tissue.
Mice with conditional deletion of Panx1 in astrocytes and neu-
rons, which we generated from Panx1 KO-first mice using FLP
deleter and cell-type specific Cre mice, are shown to exhibit
ectopic Cre expression with non-specific Panx1 downregula-
tion in the tail of 16.7% NFH-Cre:Panx1f/f and 52.6% GFAP-
Cre:Panx1f/f. This indicates the importance of careful monitoring
of transgenic Panx1 KO mice for colony stability. To this end,
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FIGURE 4 | Schematic view of the generation of conditional GFAP-Cre
and NFH-Cre Panx1 tm1a(KOMP)Wtsi mice. Mice homozygous for the
“knockout-first” allele are expected to have a null phenotype due to the
splicing of exon 1 to a lacZ trapping element and disruption of Panx1 mRNA
expression. The insertion cassette is flanked by FRT recombination sites that
allow flippase recombinase to remove the gene-trapping cassette, hereby
converting the “knockout-first” allele to a conditional allele (loxP sites flanking
exon 2) and restoring Panx1 gene expression/activity. Upon removal of the
floxed exon 2 with Cre recombinases, transcription of this Panx1 allele
generates a frameshift mutation and premature stop codon, which triggers
nonsense mediated decay of the transcript. Adapted from
www.KOMP.org.
FIGURE 5 | Ectopic activity of Cre recombinase. (Top) Breeding scheme
of Panx1f/f mice and conditional Panx1 knockout mice (mGFAP-Cre:Panx1f/f
and NFH-Cre-Panx1f/f) used to evaluate Panx1 mRNA expression.
(Bottom) Table showing Panx1 expression determined by tail qPCR of
conditional Panx1 knockout and in Panx1f/f mice, which were generated as
shown in top part. Animals were considered to have ectopic Cre activity if
they showed less than 80% of Panx1 mRNA expression compared to that
found in WT mice.
we provide a useful molecular biological approach using tail
biopsies.
In contrast to standard KO designs using targeted deletion,
the KO-first approach leaves the Panx1 gene intact and Panx1
mRNA truncation depends on splicing Panx1 exon1 to a trap-
ping element consisting of splice acceptor and polyadenylation
site contained in the targeting cassette (International Mouse
Knockout Consortium et al., 2007). However, the function of
this RNA processing module can be bypassed through alternative
splicing due to inefficiency in the splice acceptor-polyAmodule or
the presence of additional, downstream regulatory elements. This
inefficiency is likely the cause of the hypomorphic phenotype that
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FIGURE 6 | Conditional deletion of Panx1. Confocal images of trigeminal
ganglia showing expression of Panx1 in satellite glial cells and neurons in
Panx1f/f (A,D), GFAP-Cre:Panx1f/f (B,E) and NFH-Cre:Panx1f/f (C,F) mice.
The cell-specific markers NeuN and glutamine synthase (GS) were used to
identify neurons (arrowheads) and glial cells (arrows), respectively. Panx1
immunostaining is evident in both neurons and glial cells of Panx1f/f
mouse ganglion (A,D). In GFAP-Cre:Panx1f/f mice Panx1 immunoreactivity
(red) is observed in neurons and not in glial cells (B,E). Conversely, in
NFH-Cre:Panx1f/f mice Panx1 immunoreactivity (red) is observed in glial
cells and not in neurons (C,F). Note in panel (F) the faint immunoreactivity
for Panx1 that colocalizes with neurons but actually corresponds to Panx1
expression in glial cells enwrapping the neuronal cell bodies. Images were
obtained with a Olympus Fluoview 300 confocal laser scanning microscope
equipped with 40× water-immersion lens (0.80 NA), U.V., and laser lines
and appropriate filter sets. Bar: 50μm; magnification in insets 2× that in
main panels.
we report in Panx1 KO-first mice which featured a residual 30%
Panx1 mRNA in several tissues. Such hypomorphic phenotype
has been previously described for other targeted genes (Meyers
et al., 1998; Nagy et al., 1998).
The remaining Panx1 transcripts present in the KO-first tis-
sues is not sufficient to revert the KO to a WT phenotype.
Indeed, immunohistochemistry of trigeminal ganglia, a tissue
that displays high levels of Panx1 mRNA, did not reveal the
presence of Panx1 protein in the KO-first mice (Figure 3).
Similarly, previous studies reported the absence of Panx1 pro-
tein in distinct tissues and cells (hippocampus, kidney, astro-
cytes, microglia, erythrocytes, airway epithelia cells) derived from
these Panx1 KO-first mice (Seminario-Vidal et al., 2011; Qiu
et al., 2011; Santiago et al., 2011; Hanner et al., 2012; Rigato
et al., 2012; Suadicani et al., 2012). However, concerns regard-
ing antibody specificity were raised in a study in which another
Panx1 KO mouse line was investigated (Bargiotas et al., 2011).
In that study, only one out of four Panx1 antibodies tested indi-
cated absence of a ∼47 kDa band on western blots of Panx1
KO brain tissues (Bargiotas et al., 2011). In contrast to that
report, a reduction or lack of Panx1 bands on western blots
of tissues from two mouse lines (KOMP and Genentech) was
recently reported using five different antibodies (Cone et al.,
2013). Importantly, Cone et al. (2013) provided clear evidence
that differences in patterns and intensities of bands are not
restricted to the antibody sources, but is also found between
Panx1 KOmouse lines and between tissues of the same transgenic
mouse.
At present it is premature to conclude whether or not
Panx1 protein is still present in the KO-first mice or even
in other Panx1 KO mouse lines. Still, even if low levels
of Panx1 protein would be present, the KOMP mice are
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functional Panx1 KOs. Evidence of such are our recent report
showing no significant differences in animal behavior, tissue
and cell physiology, and even protein expression between
the Panx1 KO-first and the Panx1−/− mice (Santiago et al.,
2011). Taking into consideration the similarities between these
two mouse lines together with our present findings show-
ing that Panx1 KO-first express significantly higher levels of
Panx1 transcripts than Panx1−/− mice (Figure 2), 70% knock
down of Panx1 transcript appears sufficient to produce a
functional KO.
As global deletions of single genes might lead to prema-
ture lethality, conditional gene disruption offers the possibility
to investigate the role of a protein in specific cell-types dur-
ing development. The Cre/lox system is a simple two com-
ponent genetic tool, whereby under the control of a defined
promoter Cre recombinase can be restricted to a specific tis-
sue or cell-type (Nagy, 2000). However, recent reports show
that Cre expression is not often strictly confined to the desired
cells, often leading to spontaneously ectopic Cre activity (Eckardt
et al., 2004). Furthermore, the efficiency of Cre recombination
is variable and may be lost. Also, Cre expression may result in
pleiotropic effects (Lee et al., 2006; Schulz et al., 2007;Wellershaus
et al., 2008), including cell toxicity (Schmidt-Supprian and
Rajewsky, 2007; Requardt et al., 2009). These reports show-
ing non-homogeneity in cell-type specific target gene disrup-
tion, may have major impact on the experimental outcome.
Therefore, individual mice with non-cell-type specific recom-
bination (ectopic Cre activity) or reduced Cre activity have to
be identified and discarded and the extent of the Cre-mediated
gene ablation, here Panx1, must be correlated with phenotypic
alterations.
As previously reported for the hGFAP-Cre: Cx43f/f mice
(Requardt et al., 2009), we reveal a limitation of GFAP-
Cre:Panx1f/f and NFH-Cre:Panx1f/f mice, spontaneous ectopic
Panx1 gene disruption, that requires a rigorous quality control.
We have observed ectopic GFAP-Cre and NFH-Cre medi-
ated recombination, which might be caused by spontaneous
transgene rearrangements (Schulz et al., 2007), or other epi-
genetic mechanisms suggested to lead to evolutionary selec-
tion against Cre activity (Lee et al., 2006; Requardt et al.,
2009). Individual genotyping PCR to detect Cre on the DNA
level does not necessarily indicate the presence or absence
of gene disruption in a specific cell-type, and analyses of
the efficacy of disruption is required. We suggest tail-biopsy
qRT-PCR for quality control to pre-experimentally ensure that
Panx1 expression levels in the tail are unaffected by GFAP-
or NFH-Cre directed Cre activity. This simple control moni-
tors ectopic Cre activity. The Cre recombination status in the
colony must be properly monitored by routine testing of the off-
spring obtained from all breeding pairs, to ensure cell-specific
Cre activity and Panx1 gene disruption. Otherwise, unfortu-
nate choice of parental animals with ectopic or non-functional
Cre may increase the number of these mice in the colony dur-
ing the following generations. For experimental animals, a good
strategy to validate cell-specific Panx1 gene disruption is the
post-experimental confirmation of cell-specific Cre activity and
Panx1 deletion using immunohistochemical approaches in every
individual mouse and to correlate the index of gene inactivation
with phenotypical alterations. Indeed, our immunohistochemical
studies indicated significant reduction of Panx1 expression in
satellite glial cells and neurons of the trigeminal ganglia of
GFAP-Cre:Panx1f/f and NFH-Cre:Panx1f/f mice which did not
show ectopic Cre expression. The lack of complete cell-type
specific deletion of Panx1 in these conditional KO mice may
be related to the efficiency of GFAP and NFH recombination
which could be checked using a reporter mouse line. Using
such an approach, we estimated that 80% astrocytes and 70%
pyramidal neurons of the hippocampus are recombined when
using the mGFAP-Cre and NFH-Cre lines (data not shown).
These values are in accordance with previous reports using
these Cre mouse lines (Hirasawa et al., 2001; Garcia et al.,
2004).
Panx1 has been shown to be a major ATP release chan-
nel, which is expressed in all cells releasing ATP (Dahl and
Keane, 2012). Panx1 channels also interact with other proteins,
such as the purinergic receptor P2X7 and possibly inflamma-
some components involved in the innate immune response and
associated secondary cell death (Pelegrin and Surprenant, 2006;
Locovei et al., 2007; Silverman et al., 2009), thus responsi-
ble for amplification of the primary lesion in CNS trauma,
stroke and epilepsy (Bergfeld and Forrester, 1992; De Rivero
Vaccari et al., 2009; Santiago et al., 2011). Recently, it has been
shown that Panx1 is involved in the fusion of T cell mem-
brane with the human immunodeficiency virus (Seror et al.,
2011). In all these processes Panx1-mediated ATP release is
an early signal event in which Panx1 acts as a signal ampli-
fier and is therefore an obvious target for the development
of innovative therapeutic approaches. Advantages of Panx1 as
a drug target are that it is accessible to drugs and Panx1
inhibitors are already available and FDA approved, such as
the anti-malaria drug mefloquine and the gouty arthritis drug
probenecid. However, more research is required to identify
whether Panx1 has additional roles under physiological and
pathological conditions in order to avoid undesirable side effects
when targeting it.
We conclude that mice with Panx1modulation, specifically the
multi-purpose Panx1 KO-first mice, represent a suitable model
to investigate these questions. However, in this model and in
many others using this strategy, the expression levels of the genes
of interest must be carefully monitored to allow for a correct
interpretation of the experimental findings.
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